Novo Nordisk A/S - Share repurchase programme
On 7 August 2009 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an
amount up to DKK 2.4 billion in the period from 10 August 2009 to 18
December 2009.
Since the announcement as of 12 October 2009, the following
transactions have been made under the programme:
Number of Average Transaction value,
shares purchase price DKK
Accumulated, last
announcement 3,453,000 1,099,368,013
12 October 2009 65,000 322.5260 20,964,190
13 October 2009 100,000 322.2899 32,228,990
14 October 2009 115,000 320.4020 36,846,230
15 October 2009 70,000 322.0800 22,545,600
16 October 2009 75,000 323.1000 24,232,500
Accumulated under
the programme 3,878,000 1,236,185,523
With the transactions stated above, Novo Nordisk owns a total of
28,714,808 treasury shares, corresponding to 4.6% of the share
capital. The total amount of shares in the company is 620,000,000
including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 28,500
employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
Further information:
Media: Investors:
Outside North America: Outside North America:
Mette Kruse Danielsen Mads Veggerby Lausten
Tel: (+45) 4442 3883 Tel: (+45) 4443 7919
mkd@novonordisk.com mlau@novonordisk.com
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
krop@novonordisk.com
In North America: In North America:
Sean Clements Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com hrmm@novonordisk.com
Company Announcement no 61/2009
